Immunization of healthy people against influenza virus infections.
Conditions
Interventions
Trade Name: FluvalAB Influenza Vaccine
Product Name: FluvalAB Influenza Vaccine
Pharmaceutical Form: Injection*
Other descriptive name: Influenza A/Solomon Islands/3/2006 (H1N1)-like IVR-145 reass. st
Sponsors
Omninvest Ltd.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Healthy adult volunteers above 18 years, both males and females. Full contractual capacity. Negative pregnancy test in case of women with childbearing capacity. Informed consent of the volunteers. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: Allergy on egg or on any ingredient of the vaccine. Pregnancy or breast feeding. Immunsuppressive therapy in 36 month prior to clinical trial. Active neoplasm. Corticosteroid therapy in progress. Vaccination in 4 weeks prior to clinical trial. Flu vaccination in 6 month prior to clinical trial. Acute febrile respiratory disease in 1 week prior to clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: Assessment of immunogenicity of the vaccine by serology testing from blood samples taken 21-28 days after vaccination. Assessment of safety of the vaccine on the basis of adverse events.;Secondary Objective: ;Primary end point(s): Assessment of the fact that in consequence of the vaccination ratio of seroconversion was greater than 40% and 30% in age groups respectively. Assessment of the fact that in consequence of the vaccination increase in geometric mean titer was greater than 2,5 and 2 in age groups respectively. Assessment of the fact that in consequence of the vaccination ratio of HAI titres >= 1:40 was greater than 70 and 60 % in age groups respectively. | — |
Countries
Hungary
Outcome results
None listed